Table 4.

Factors influencing survival of AML patients relapsing after alloHCT

	Univariate			Multivariate
Variable	N	RR (95% CI)	P-value	RR (95% CI)	P-value
Time from HCT to relapse			<0.0001		<0.0001
< 6m	774	1.00		1.00
6m-2y	702	0.60 (0.53–0.66)	<0.0001	0.55 (0.50–0.62)	<0.0001
2–3y	138	0.40 (0.33–0.50)	<0.0001	0.39 (0.32–0.49)	<0.0001
≥ 3y	174	0.30 (0.24–0.37)	<0.0001	0.28 (0.23–0.35)	<0.0001
Year of HCT
1990–2000	745	1.00		NS	NS
2001–2010	1043	1.19 (1.08–1.32)	0.0006
Age			<0.0001		<0.0001
≤ 18y	656	1.00		1.00
19–40y	433	0.86 (0.75–0.98)	0.02	1.00 (0.87–1.15)	0.10
≥41y	699	1.27 (1.13–1.42)	<0.0001	1.42 (1.24–1.64)	<0.0001
Gender
Male	988	1.00		NS	NS
Female	800	0.98 (0.88–1.08)	0.63
Cytogenetics			<0.0001		0.02
Favorable	138	1.00		1.00
Intermediate/Norm	805	1.27 (1.04–1.56)	0.02	1.15 (0.94–1.41)	0.18
Unfavorable	334	1.64 (1.32–2.04)	<0.0001	1.37 (1.09–1.71)	0.01
Unknown	511	1.22 (0.99–1.51)	0.06	1.13 (0.91–1.39)	0.27
Conditioning
MA	1374	1.00		1.00
RIC/NMA	414	1.18 (1.05–1.33)	0.01	0.77 (0.66–0.88)	0.0002
Donor Type			<0.0001		0.0007
RD/URD-Matched	1387	1.00		1.00
URD-Mismatched	56	1.65 (1.25–2.17)	0.0003	1.61 (1.22–2.13)	0.0008
URD-Unknown	113	1.10 (0.90–1.35)	0.37	1.10 (0.89–1.36)	0.37
Cord Blood	232	1.38 (1.19–1.60)	<0.0001	1.23 (1.06–1.42)	0.01
Active GVHD at relapse			0.20		0.0002
No	1028	1.00		1.00
Yes	727	1.10 (0.99–1.21)	0.07	1.25 (1.13–1.39)	<0.0001
Unknown	33	1.01 (0.70–1.47)	0.95	1.05 (0.72–1.52)	0.80